Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Clinical trials of WR-2721 with radiation therapy

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
; ; ; ; ; ;

The radioprotector with clinical protential, S-2-(3 aminopropylamino)-ethylphosphorotioic acid (WR-2721) is undergoing two Phase I trials. The objectives of these trials are 1) to determine the maximum tolerated dose (MTD) of WR-2721 in a single dose and 2) to determine the highest dose of WR-2721 that can be tolerated daily in the greatest number of fractions per week.A total of 65 patients have been treated. The single maximum tolerated dose has not yet been reached, though 740 mg/m/sup 2/ is well tolerated. A single dose of 910 mg/m/sup 2/ has been successfully administered to one patient. The multiple dose MTD is at an early stage with patients currently receiving 170 mg/m/sup 2/ four times a week. Among the toxicities noted in both trials there have been three patients who have had allergic reactions including one which was life-threatening. Phase II studies are planned and will begin when the maximum tolerated dose is established from each Phase I trial.

Research Organization:
Univ. of Pennsylvania School of Medicine, Philadelphia
OSTI ID:
6716667
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:3/4; ISSN IOBPD
Country of Publication:
United States
Language:
English

Similar Records

Phase I trials of WR-2721 and cis-platinum
Conference · Sat Sep 01 00:00:00 EDT 1984 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6003648
A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies
Journal Article · Tue Dec 31 23:00:00 EST 1991 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:5514479
Phase I controlled trials of WR-2721 and cyclophosphamide
Conference · Sat Sep 01 00:00:00 EDT 1984 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6166463

Related Subjects

550603* -- Medicine-- External Radiation in Therapy-- (1980-)
560151 -- Radiation Effects on Animals-- Man
560306 -- Chemicals Metabolism & Toxicology-- Man-- (-1987)
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALLERGY
CARDIOVASCULAR DISEASES
DISEASES
DRUGS
HYPERTENSION
MEDICINE
NUCLEAR MEDICINE
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC SULFUR COMPOUNDS
PATHOLOGICAL CHANGES
PATIENTS
RADIOLOGY
RADIOPROTECTIVE SUBSTANCES
RADIOTHERAPY
SIDE EFFECTS
SYMPTOMS
THERAPY
THIOIC ACIDS
THIOLS
VASCULAR DISEASES
VOMITING